XOMA Corp (NASDAQ: XOMA)

XOMA is having a strong day in the market today, and for good reason. The company reported its earnings for the fourth quarter of 2015 as expected yesterday after the closing bell. The earnings release was overwhelmingly positive, leading to investor excitement throughout. Today, we'll talk about what we saw from earnings, how investors reacted to the news, and what we can expect to see from XOMA moving forward. So, let's get right to it...

Trade smarter and make more money with Tradespoon!

XOMA Produces Overwhelmingly Positive Earnings

As mentioned above, XOMA is having an incredibly strong day in the market after reporting exceptional earnings after the closing bell yesterday. Here's what we saw from the report:

  • Earnings Per Share – In terms of earnings per share, XOMA produced well ahead of expectations. In the fourth quarter analysts expected that the company would produce earnings in the amount of $0.15 per share. However, they actually reported revenue in the amount of $0.21 per share, well ahead of analyst expectations.
  • Revenue – While earnings was overwhelmingly positive, XOMA posted one of the strongest revenue beats I've ever seen. According to TheStreet, the company was expected to produce revenue in the amount of $4.01 million. However, in the quarter, the company actually produced revenue in the amount of $48.18 million, more than 12 times expectations!

As you can see from the data above, the earnings release was overwhelmingly positive. In a statement, the company had the following to say with regard to the incredible results from the quarter:

The increase in full-year and fourth quarter 2015 revenues was due primarily to our licensing activity in the fourth quarter, including a $37 million upfront payment from Novartis, a $5 million upfront payment from Novo Nordisk and a $3.8 million payment from Pfizer.”

The CEO of XOMA, John Varian followed up with the statement below:

The transformation we initiated in the third quarter of last year – and now have completed in less than six months – was considerable in its scale and complexity, but essential to position XOMA to deliver our promising portfolio of endocrine assets...”

How The Market Reacted To The News

As investors, we know that the news moves the market. So, it's no surprise that news of an overwhelmingly positive earnings report from XOMA would move the needle for the stock in a big way. Currently (11:12), the stock is trading at $0.93 per share after a gain of $0.04 per share or 5.06% thus far today.

What We Can Expect To See Moving Forward

Overall, I have a relatively bullish opinion of what we can expect to see from XOMA moving forward. First and foremost, I'm incredibly impressed with the partners the company has been able to bring on board over the past few months. Bringing in some of the largest players on the biotechnology field will likely lead to incredible improvements in XOMA's business as a whole. On top of that, I like what I'm seeing with regard to the pipeline the company currently has. At the moment, they have 3 preclinical candidates as well as one candidate in the end of Phase 1 and one candidate in the midst of Phase 2 testing. While I am a bit concerned about the company's cash flow, I believe that the positive aspects of the stock largely outweigh anything negative there is to say.

Don't waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think XOMA is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of Flickr]

Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

NO COMMENTS

Leave a Reply